Rahamimov, R1; Yusim, A2; Winkler, J1; Mashraki, T2; Gafter, U1; Mor, E2 Author Information

1Dept. of Transplantation, Rabin Medical Center, Petach-Tikva, Israel;2Institute of Chemical Pathology, Sheba Medical Center, Ramat-Gan, Israel.

After kidney transplantation, recurrence of primary or secondary glomerulonephritis or de novo nephropathy occurs quite commonly, globally involving up to 20%–25% of patients. Different incidences, timings of recurrence, and rates of aggressiveness have been reported according to the specific disorder observed. A correct diagnosis is mandatory but not all the time easy to be obtained. Specific therapies must be taken into account according to the diagnosed underlying disease.

Cyclosporin is poorly tolerated in patients with amyloidosis due to familial mediterranean fever who are receiving colchicine. There is a high incidence of gastrointestinal side-effects and muscle weakness, both of which are reversible on stopping cyclosporin. Thus in patients with amyloidosis secondary to familial mediterranean fever treated with colchicine, the use of cyclosporin as an immunosuppressive agent may be restricted.